About Missouri Cannabis Testing
Missouri Cannabis Testing, a Division of EKG Labs, was founded in 2013 by Jennifer Eagan, Allen Kesselring, and Katie Grayson. The founders have spent the majority of their careers working within contract research laboratories focused on combination product, medical device, and pharmaceutical development. A little over 7 years ago, the opportunity arose for Eagan, Kesselring, and Grayson to leverage their experience and history together to create a new business endeavor. Drawing on their collective 50+ years of experience working with DEA controlled substances (including CBD, THC, general cannabinoids and their metabolites), the team decided to utilize their knowledge in pharmaceutical science and passion for medical cannabis to form the medicinal marijuana division, MoCann Testing. Their mission is to help individuals across the state ensure they have access to safe medical marijuana through accurate sample testing and quality results.
Meet the Team
Ms. Natalie Brown began her career at EKG Labs, an analytical laboratory that supports medical device and pharmaceutical companies seeking to fast-track their product development, upon graduating from Missouri Baptist University with a Bachelor of Science in Chemistry. She executed procedures according to cGXP regulations, worked with various DEA controlled substances, and maintained, operated, and qualified analytical instruments.
In 2019, Natalie proposed expanding into new areas, and she worked together with EKG’s founding members to add a medical marijuana division to company, Missouri Cannabis Testing. MoCann Testing’s mission is to help individuals across the state ensure they have access to safe medical marijuana through accurate sample testing and quality results. She has been actively involved in executing strategies as directed from the management team, developing and promoting company policies, planning and monitoring the day-to-day operations of the company while also serving as the primary liaison for the company. In 2020, Natalie joined the MoCannTrade Health and Education Training committee. The committee focuses on successful education of stakeholders in the community, including patients and physicians. From healthcare systems, physicians, providers and patients, this committee researches & defines best practices with stakeholders to ensure a safe, responsible and successful program implementation.
After graduating from Monmouth College, Ms. Grayson began her career at Ethyl Petroleum where she supported quality control and analytical services. In 1996, she joined Chemir Analytical Services where she filled several positions and then established the company’s first Quality Assurance Unit. Ms. Grayson played a key role in developing the organization’s expertise in testing pharmaceutical and medical device products including extractable and leachable testing, impurity analysis, and method validation. Ms. Grayson spent time with both UPM Pharmaceuticals and Chemic Laboratories before transitioning to Evans Analytical Group, Life Science Division (Cyanta) in 2010, where she managed the Business Development and Technical Affairs groups.
In 2017, Ms. Grayson completed Goldman Sachs 10,000 Small Businesses National Program at Babson College where she enhanced her natural leadership ability, negotiation skills and experience in building a company. This program is designed to create jobs and economic opportunities by providing access to education, capital and business support services. To date, more than 10,000 business owners have graduated from the program across all 50 states in the US, Puerto Rico and Washington D.C. Katie serves as the Chief Executive Officer for MoCann Testing, the state’s first operational medical marijuana testing laboratory!
Dr. Kesselring received his doctorate in Organic Chemistry from Washington University in St. Louis, MO. He was also instrumental in establishing a research laboratory for Dr. Scott Gilbertson in the Toxicology Department of the University of Texas Medical Branch at Galveston. Then, in 2005, he joined Chemir Analytical Services where he was responsible for driving a variety of research and development programs dealing with method development and validation, extractables and leachables, and impurities and degradants in pharmaceutical and medical device products. Dr. Kesselring also helped lead Chemir’s newly developed division, Cyanta Analytical Services. In 2008, he took on the role of Director of Analytical Operations and was later promoted to Vice President and General Manager. When Cyanta was purchased by Evans Analytical Group, Dr. Kesselring continued his leadership role as Managing Director of the Life Sciences Division.
Dr. Kesselring has become an industry recognized expert in extractable and leachable programs, authoring many presentations, papers, posters, and articles regarding this topic.
As Chief Science Officer of MoCann Testing, Dr. Kesselring is actively overseeing the development and implementation of Missouri rule compliant, cannabis test methods. These methods are critical for the successful clearance of safe and effective cannabis based medicinal treatments here in Missouri.
Dr. Kesselring also has uniquely positioned science-based business insight as a member of the Missouri Medical Cannabis Trade Association advisory board member of the Manufacturing and Testing committee. While testing is the foundation and backbone of Medicinal Cannabis product safety and efficacy, Dr. Kesselring also deeply understands the need to find efficient intersection of patient and industry requirements and will work towards policy and protocols that resourcefully meet the needs of both suppliers and patients.
After graduating from the University of Missouri – Saint Louis in 2000, Ms. Eagan began her career working as a Quality Assurance Associate at the Missouri-Illinois Region of the America Red Cross. In 2007, Ms. Eagan accepted a similar role at Cyanta Analytical Services where she co-established and managed their Quality System. In 2010, Ms. Eagan was promoted to Director of Quality Assurance and became solely responsible for maintaining, enforcing, and defending their Quality System. Ms. Eagan has an immaculate quality record as she has hosted several Regulatory Inspections with zero observations.